McCullough M, Caraballo C, Ravindra NG, et al. - By performing this retrospective cohort study of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), researchers examined the link between neurohormonal blockade (NHB) blockade and outcomes in patients with left ventricular assist devices (LVADs). The participants were recruited from more than 170 centers across the United States and Canada. Stratification of patients was performed on the basis of exposure to NHB. Survival at 4 years and quality of life at 2 years were assessed using Kansas City Cardiomyopathy Questionnaire scores and a 6-minute walk test. Improved survival and quality of life in correlation with continued treatment were observed among patients with LVADs who tolerated NHB therapy. The commencement, as well as maintenance of guideline-directed medical therapy, was suggested as the possible optimal heart failure regimen for patients following LVAD implant.